The Office of the Inspector General of the Health and Human Services Departments said last week that it will begin investigating whether the Centers for Medicare & Medicaid Services properly monitors its Medicaid Drug Rebate Program. The investigation comes after CMS reported that Mylan (NSDQ:MYL) underpaid Medicaid by not paying appropriate rebates. The Canonsburg, Penn.-based company said it would pay $465 million to settle the claims with the Justice Department, but the federal government has not confirmed such a deal.
The federal watchdog’s office will also investigate whether other pharmaceutical companies have complied with the drug rebate policies or have similarly underpaid Medicaid.
Get the full story at our sister site, Drug Delivery Business News.
The post Federal watchdog to investigate CMS drug rebate program appeared first on MassDevice.